Guosheng Yin | Academic Influence

Guosheng Yin's AcademicInfluence.com Rankings

Guosheng Yin

Computer Science

#6880

World Rank

#7246

Historical Rank

Data Science

#284

World Rank

#289

Historical Rank

computer-science Degrees

Guosheng Yin

Mathematics

#6732

World Rank

#9274

Historical Rank

Statistics

#927

World Rank

#1021

Historical Rank

mathematics Degrees

Download Badge

Computer Science
Mathematics

Guosheng Yin's Degrees

PhD Statistics Stanford University
Masters Statistics Stanford University
Bachelors Mathematics Peking University

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Guosheng Yin Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Guosheng Yin is a statistician, data scientist, educator and researcher in Biostatistics, Statistics, machine learning, and AI. Presently, Guosheng Yin is Chair in Statistics in Department of Mathematics at Imperial College London. Previously, he served as the Head of Department and the Patrick S C Poon Endowed Chair in Statistics and Actuarial Science, at the University of Hong Kong. Before he joined the University of Hong Kong, Yin worked at the University of Texas M.D. Anderson Cancer Center till 2009 as a tenured Associate Professor of Biostatistics.

(See a Problem?)

Guosheng Yin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Fundamentals of Clinical Trials (2012) (598)
Outlier detection for high-dimensional data (2015) (192)
Bayesian dose finding in oncology for drug combinations by copula regression (2009) (156)
Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials (2009) (154)
Cure rate models: A unified approach (2005) (153)
Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (2006) (146)
Semiparametric Transformation Models for Survival Data With a Cure Fraction (2006) (139)
Bayesian Quantile Regression for Longitudinal Studies with Nonignorable Missing Data (2010) (132)
Nonparametric maximum likelihood approach to multiple change-point problems (2014) (120)
A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (2009) (113)
Clinical Trial Design: Bayesian and Frequentist Adaptive Methods (2011) (111)
Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer (2008) (105)
Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes (2009) (96)
Concentrations of toxic metals and ecological risk assessment for sediments of major freshwater lakes in China (2015) (91)
Bayesian generalized method of moments (2009) (84)
Conditional quantile screening in ultrahigh-dimensional heterogeneous data (2015) (80)
Sequential continual reassessment method for two‐dimensional dose finding (2008) (78)
Phase II trial design with Bayesian adaptive randomization and predictive probability (2012) (71)
Additive hazards model with multivariate failure time data (2004) (70)
Bayesian optimal interval design for dose finding in drug-combination trials (2017) (69)
Maximum Likelihood Estimation for the Proportional Odds Model With Random Effects (2005) (61)
Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization (2012) (60)
Quantile Regression Models with Multivariate Failure Time Data (2005) (60)
BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. (2013) (60)
Robust EM Continual Reassessment Method in Oncology Dose Finding (2011) (56)
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. (2011) (55)
Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes (2007) (49)
A General Class of Bayesian Survival Models with Zero and Nonzero Cure Fractions (2005) (43)
Bayesian Cure Rate Frailty Models with Application to a Root Canal Therapy Study (2005) (43)
Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. (2019) (42)
Power-Transformed Linear Quantile Regression With Censored Data (2008) (40)
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. (2013) (38)
Semiparametric median residual life model and inference (2010) (38)
A Class of Bayesian Shared Gamma Frailty Models with Multivariate Failure Time Data (2005) (37)
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials (2017) (35)
Bayesian randomized clinical trials: From fixed to adaptive design. (2017) (33)
Cure Rate Model With Mismeasured Covariates Under Transformation (2008) (32)
Escalation with overdose control for phase I drug‐combination trials (2013) (30)
Comparison of Transmissibility of Coronavirus Between Symptomatic and Asymptomatic Patients: Reanalysis of the Ningbo COVID-19 Data (2020) (29)
Nonparametric overdose control with late-onset toxicity in phase I clinical trials. (2017) (26)
Dose–Response Curve Estimation: A Semiparametric Mixture Approach (2011) (25)
Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy (2010) (25)
Bayesian transformation cure frailty models with multivariate failure time data (2008) (24)
CENSORED QUANTILE REGRESSION WITH COVARIATE MEASUREMENT ERRORS (2011) (24)
Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. (2015) (24)
Bayesian hybrid dose‐finding design in phase I oncology clinical trials (2011) (23)
Partially Linear Additive Hazards Regression With Varying Coefficients (2008) (23)
Pooling Information Across Different Studies and Oligonucleotide Chip Types to Identify Prognostic Genes for Lung Cancer (2005) (23)
Model checking for additive hazards model with multivariate survival data (2007) (22)
Bayesian Semiparametric Cure Rate Model with an Unknown Threshold (2008) (22)
Inference for a Class of Transformed Hazards Models (2005) (22)
On the usefulness of outcome-adaptive randomization. (2011) (21)
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials (2021) (21)
Smoothed and Corrected Score Approach to Censored Quantile Regression With Measurement Errors (2015) (20)
Change-point detection in multinomial data with a large number of categories (2018) (20)
Comments on ‘Competing designs for drug combination in phase I dose‐finding clinical trials’ by M‐K. Riviere, F. Dubois, and S. Zohar (2015) (19)
Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials (2013) (19)
Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015 (2019) (17)
Cure Rate Quantile Regression for Censored Data With a Survival Fraction (2013) (17)
Censored cumulative residual independent screening for ultrahigh-dimensional survival data (2018) (16)
Control of Type I Error Rates in Bayesian Sequential Designs (2019) (16)
Ensemble Approaches to Estimating the Population Mean with Missing Response (2017) (15)
Stochastic Generalized Method of Moments (2011) (14)
Comparison of transmissibility of coronavirus between symptomatic and asymptomatic patients: Reanalysis of the Ningbo COVID-19 data. (2020) (14)
Bayes factor and posterior probability: Complementary statistical evidence to p-value. (2015) (14)
A general transformation class of semiparametric cure rate frailty models (2012) (14)
Two‐stage dose finding for cytostatic agents in phase I oncology trials (2013) (14)
Bayesian frailty models based on box-cox transformed hazards (2005) (13)
Reconnecting p-Value and Posterior Probability Under One- and Two-Sided Tests (2020) (13)
Efficient Algorithm for Computing Maximum Likelihood Estimates in Linear Transformation Models (2006) (12)
Generalized method of moments estimation for linear regression with clustered failure time data (2009) (12)
Pearson-type goodness-of-fit test with bootstrap maximum likelihood estimation. (2013) (12)
Adaptive Design and Estimation in Randomized Clinical Trials with Correlated Observations (2005) (12)
Two Simulation Methods for Constructing Confidence Bands Under the Additive Risk Model (2004) (11)
Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. (2021) (11)
Uniformly most powerful Bayesian interval design for phase I dose‐finding trials (2018) (11)
Self-Designing Trial Combined with Classical Group Sequential Monitoring (2005) (10)
P-value: A Bless or A Curse for Evidence-Based Studies? (2018) (10)
Landmark cure rate models with time-dependent covariates (2017) (9)
Efficiency improvement in a class of survival models through model-free covariate incorporation (2011) (9)
Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials (2016) (9)
Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests (2017) (8)
Bayesian enhancement two‐stage design for single‐arm phase II clinical trials with binary and time‐to‐event endpoints (2018) (8)
Testing homogeneity of high-dimensional covariance matrices (2019) (8)
Boosting conditional logit model (2017) (8)
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint (2018) (8)
Phase I trial design for drug combinations with Bayesian model averaging (2015) (8)
Partitioned log-rank tests for the overall homogeneity of hazard rate functions (2017) (8)
Two‐stage adaptive randomization for delayed response in clinical trials (2014) (8)
Bayesian mixture models for complex high dimensional count data in phage display experiments (2007) (7)
Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. (2012) (6)
Generalized Method of Moments for Additive Hazards Model with Clustered Dental Survival Data (2016) (6)
Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity (2011) (6)
The Delaunay triangulation learner and its ensembles (2020) (6)
Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials (2021) (6)
Bayesian goodness-of-fit test for censored data (2009) (6)
Non‐parametric overdose control for dose finding in drug combination trials (2019) (6)
Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. (2021) (6)
Censored quantile regression with varying coefficients (2014) (5)
Entropy and Survival-based Weights to Combine Affymetrix Array Types and Analyze Differential Expression and Survival (2005) (5)
Local likelihood with time‐varying additive hazards model (2007) (5)
Multiethnic polygenic risk prediction in diverse populations through transfer learning (2022) (5)
Functional Censored Quantile Regression (2019) (5)
Functional Martingale Residual Process for High-Dimensional Cox Regression with Model Averaging (2020) (5)
Maximum likelihood estimation for incomplete multinomial data via the weaver algorithm (2018) (5)
Dynamic portfolio choice without cash (2018) (5)
Restricted mean survival time for interval‐censored data (2020) (4)
Multiple imputation for cure rate quantile regression with censored data (2017) (4)
Bayesian two‐stage dose finding for cytostatic agents via model adaptation (2016) (4)
Unit information prior for adaptive information borrowing from multiple historical datasets (2021) (4)
Subgroup Analysis in Censored Linear Regression (2021) (4)
Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials (2018) (4)
Pair Chart Test for an Early Survival Difference (2005) (4)
An alternative approach for estimating the number needed to treat for survival endpoints (2019) (4)
Multiple change-points detection in high dimension (2019) (4)
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir (2020) (4)
Bayesian Hierarchical Model for Change Point Detection in Multivariate Sequences (2021) (4)
Sieve maximum likelihood estimation for a general class of accelerated hazards models with bundled parameters (2017) (4)
Bayesian Approach for Adaptive Design (2010) (3)
PCA Rerandomization (2021) (3)
Quantile Inference with Multivariate Failure Time Data (2003) (3)
Least squares estimation of varying‐coefficient hazard regression with application to breast cancer dose‐intensity data (2009) (3)
Pooling Information Across Different Studies and Oligonucleotide Microarray Chip Types to Identify Prognostic Genes for Lung Cancer (2013) (3)
Concordance index: Surrogacy of progression-free survival for overall survival. (2021) (3)
C-index regression for recurrent event data. (2022) (3)
Bayesian Model Selection Approach to Boundary Detection with Non-Local Priors (2018) (3)
Efficient Unpaired Image Dehazing with Cyclic Perceptual-Depth Supervision (2020) (3)
Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies (2020) (3)
Nonparametric Functional Approximation with Delaunay Triangulation Learner (2019) (3)
Bayesian cure rate model accommodating multiplicative and additive covariates (2009) (3)
Adaptive iterative Hessian sketch via A-optimal subsampling (2019) (3)
START: single‐to‐double arm transition design for phase II clinical trials (2020) (3)
Bayesian enhancement two‐stage design with error control for phase II clinical trials (2020) (2)
Fast Algorithm for Generalized Multinomial Models with Ranking Data (2019) (2)
Response‐adaptive rerandomization (2021) (2)
A Systematic Review and Network Meta-Analysis for COVID-19 Treatments (2020) (2)
CFO: Calibration-free odds design for phase I/II clinical trials (2022) (2)
Bayesian Model Selection Approach to Multiple Change-Points Detection with Non-Local Prior Distributions (2019) (2)
Power computation for hypothesis testing with high-dimensional covariance matrices (2016) (2)
Biostatistics pitfalls: Lessons learned from analysis of medical data. (2019) (2)
A semiparametric regression model for oligonucleotide arrays (2003) (2)
Phase II Trial Design (2012) (2)
Approximate Bayesian computation design for phase I clinical trials (2022) (2)
Principles and Reporting of Bayesian Trials. (2020) (1)
Bayesian Knockoff Filter Using Gibbs Sampler (2021) (1)
Demystify Lindley's Paradox by Interpreting P-value as Posterior Probability (2020) (1)
Targeted Therapy Design (2012) (1)
Radical Surgery or Watchful Waiting in Prostate Cancer. (2019) (1)
Generalized partially linear single‐index model for zero‐inflated count data (2015) (1)
Dynamic portfolio selection without risk-free assets (2016) (1)
Reconstructing the Kaplan–Meier Estimator as an M-estimator (2021) (1)
A variable selection approach to multiple change-points detection with ordinal data (2020) (1)
Phase I Trial Design (2012) (1)
Testing Overall and Subpopulation Treatment Effects with Measurement Errors. (2013) (1)
Kernel-based adaptive randomization toward balance in continuous and discrete covariates (2018) (1)
Reduction in number to treat versus number needed to treat (2021) (1)
Bayesian SIR model with change points with application to the Omicron wave in Singapore (2022) (1)
Cure rate quantile regression accommodating both finite and infinite survival times (2017) (1)
Varying‐association copula models for multivariate survival data (2018) (1)
The GR2D2 Estimator for the Precision Matrices (2022) (1)
QUANTILE REGRESSION WITH COVARIATE MEASUREMENT ERRORS (2011) (0)
Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis (2022) (0)
Comparison of Transmissibility of Coronavirus Between Symptomatic and Asymptomatic Patients: Reanalysis of the Ningbo COVID-19 Data (Preprint) (2020) (0)
Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes. (2023) (0)
Supplementary Materials for Subgroup Analysis in Censored Linear Regression (2019) (0)
Current Status on Treatments and Clinical Trials for COVID-19 (Preprint) (2020) (0)
Statistical Methods in Clinical Trial Design (2017) (0)
Drug‐Combination Trials (2012) (0)
Unit information prior for incorporating real-world evidence into randomized controlled trials (2023) (0)
Erratum: Partially linear additive hazards regression with varying coefficients (Journal ofthe American Statistical Association (2008) (1200-1213)) (2008) (0)
Gaussian Mixture Models with Concave Penalized Fusion (0)
Title Testing overall and subpopulation treatment effects withmeasurement errors (2013) (0)
Bayesian Model Averaging Continual Reassessment Method BMA-CRM (2009) (0)
Title Bayesian phase I / II adaptively randomized oncology trials withcombined drugs (2011) (0)
Sparse Concordance‐based Ordinal Classification (2022) (0)
A general transformation class of semiparametric cure rate frailty models (2012) (0)
AVERAGE HOLDING PRICE (2018) (0)
Bootstrap aggregating continual reassessment method with application to drug-combination trials (2016) (0)
Omnibus test for restricted mean survival time based on influence function. (2023) (0)
Partitioned log-rank tests for the overall homogeneity of hazard rate functions (2016) (0)
Title Bayesian Data Augmentation Dose Finding with ContinualReassessment Method and Delayed Toxicity (2014) (0)
Title Pearson-type goodness-offit test with bootstrap maximumlikelihood estimation (2013) (0)
Reconstruct Kaplan--Meier Estimator as M-estimator and Its Confidence Band (2020) (0)
Random walk and parallel crossing bayesian optimal interval design for dose finding with combined drugs (2017) (0)
Convergence rates of the blocked Gibbs sampler with random scan in the Wasserstein metric (2020) (0)
Frequentist versus Bayesian Statistics (2012) (0)
Issue Information (2019) (0)
Issue Information (2018) (0)
Title Bootstrap aggregating continual reassessment method for dosefinding in drug-combination trials (2017) (0)
Overview of adaptive randomization (2015) (0)
Bayesian Log-Rank Test (2023) (0)
Issue Information (2018) (0)
Censored cumulative residual independent screening for ultrahigh-dimensional survival data (2017) (0)
Model aggregation for doubly divided data with large size and large dimension (2022) (0)
Causal Effect of Functional Treatment (2022) (0)
Nonparametric Functional Approximation with Delaunay Triangulation (2019) (0)
Triangular Concordance Learning of Networks (2022) (0)
Title Bayesian Dose Finding for Combined Drugs with Discrete andContinuous Doses (2012) (0)
Issue Information (2018) (0)
Bayesian Knockoff Filter (2021) (0)
Late‐Onset Toxicity (2012) (0)
Phase III Trial Design (2012) (0)
Amendments and Corrections: 'Generalized method of moments estimation for linear regression with clustered failure time data' (2009) (0)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2019) (0)
Oncology Dose Finding Using Approximate Bayesian Computation Design (2022) (0)
Double bias correction for high-dimensional sparse additive hazards regression with covariate measurement errors (2022) (0)
Design of Noninferiority Trials for Hypofractionated vs Conventional Radiotherapy Among Patients With Cancer. (2019) (0)
Submitted to the Annals of Statistics CHANGE-POINT DETECTION IN MULTINOMIAL DATA WITH A LARGE NUMBER OF CATEGORIES By (2017) (0)
Web-based Supplementary Materials for “ Multiple Imputation for Cure Rate Quantile Regression With Censored Data ” by Yuanshan Wu and (2016) (0)
Dynamic ordering design for dose finding in drug‐combination trials (2020) (0)
Title Bayesian generalized method of moments (2009) (0)
Maximum likelihood estimation for incomplete multinomial data via the weaver algorithm (2017) (0)
Sample size re-estimation in adaptively randomized clinical trials with missing data (2015) (0)
Fast and Stable Maximum Likelihood Estimation for Incomplete Multinomial Models (2019) (0)
2 Bayesian Generalized Method of Moments 2 . 1 Generalized Linear Model (2009) (0)
Fast and Stable Maximum Likelihood Estimation for Incomplete Multinomial Data (2019) (0)
Semiparametric Reversed Mean Model for Recurrent Event Process with Informative Terminal Event (0)
Sample size re-estimation in adaptive enrichment design. (2020) (0)
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint (2017) (0)
Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages (2023) (0)
Nonparametric inference for reversed mean models with panel count data (2022) (0)
Divide and conquer for accelerated failure time model with massive time‐to‐event data (2022) (0)
Bayesian Outdoor Defect Detection (2018) (0)
Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer. (2019) (0)
Demystify Lindley’s paradox by connecting $p$-value and posterior probability (2021) (0)
Issue Information (2019) (0)
Nonlinear dimension reduction for functional data with application to clustering (2022) (0)
Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials (2016) (0)

This paper list is powered by the following services:

Other Resources About Guosheng Yin

en.wikipedia.org

What Schools Are Affiliated With Guosheng Yin?

Guosheng Yin is affiliated with the following schools: